Sang­amo's sick­le cell al­liance with Sanofi grinds to a halt as phar­ma gi­ant switch­es fo­cus to al­lo

Af­ter show­cas­ing clin­i­cal da­ta at #ASH21 for a sick­le cell dis­ease can­di­date, Sanofi has de­cid­ed to throw in the tow­el on its 8-year part­ner­ship with col­lab­o­ra­tor Sang­amo — and re­turn its rights to the can­di­date.

The gene edit­ing biotech an­nounced the “tran­si­tion” this morn­ing, sev­er­al days af­ter Sanofi told Sang­amo that the biotech was back­ing out of the deal. The Paris-based phar­ma gi­ant will be re­turn­ing its rights and oblig­a­tions on SAR445136, a zinc fin­ger nu­cle­ase gene-edit­ed cell ther­a­py back to Sang­amo by the end of June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER